Clinical Trial Update: A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

View source ↗

Summary

This update describes a clinical trial evaluating first-line ipilimumab plus nivolumab in locally advanced or metastatic non-small cell lung cancer, which is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ipilimumab (Yervoy) (ipilimumab)
• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-small Cell Lung Cancer (NSCLC) | Status: ACTIVE_NOT_RECRUITING